Immunitybio, inc. IBRX.US Overview
IBRX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
IBRX Current Performance
-5.52%
Immunitybio, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
IBRX Key Information
IBRX Revenue by Segments
Browsing restrictions can be lifted for a fee.
IBRX Net Income
Browsing restrictions can be lifted for a fee.
IBRX Cash Flow
Browsing restrictions can be lifted for a fee.
IBRX Profit Margin
Browsing restrictions can be lifted for a fee.
IBRX PE Ratio River
Browsing restrictions can be lifted for a fee.
IBRX Financial Forecast
Browsing restrictions can be lifted for a fee.
IBRX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
IBRX Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Price of IBRX
IBRX FAQ
When is IBRX's latest earnings report released?
The most recent financial report for Immunitybio, inc. (IBRX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IBRX's short-term business performance and financial health. For the latest updates on IBRX's earnings releases, visit this page regularly.
What is the operating profit of IBRX?
According to the latest financial report, Immunitybio, inc. (IBRX) reported an Operating Profit of -64.43M with an Operating Margin of -390.08% this period, representing a growth of 32.32% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is IBRX's revenue growth?
In the latest financial report, Immunitybio, inc. (IBRX) announced revenue of 16.52M, with a Year-Over-Year growth rate of 41,192.5%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does IBRX have?
As of the end of the reporting period, Immunitybio, inc. (IBRX) had total debt of 822.56M, with a debt ratio of 2.71. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does IBRX have?
At the end of the period, Immunitybio, inc. (IBRX) held Total Cash and Cash Equivalents of 60.66M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does IBRX go with three margins increasing?
In the latest report, Immunitybio, inc. (IBRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 99.6%%, operating margin of -390.08%%, and net margin of -784.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IBRX's profit trajectory and future growth potential.
Is IBRX's EPS continuing to grow?
According to the past four quarterly reports, Immunitybio, inc. (IBRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of IBRX?
Immunitybio, inc. (IBRX)'s Free Cash Flow (FCF) for the period is -87.03M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 19.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of IBRX?
The latest valuation data shows Immunitybio, inc. (IBRX) has a Price-To-Earnings (PE) ratio of -5.09 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.